The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system
Open accessAbstract
The 2016 revised fourth edition of the World Health Organization (WHO) classification of central nervous system (CNS) tumors incorporated molecular features with histologic grading, revolutionizing how oncologists conceptualize primary brain and spinal cord tumors as well as providing new insights into their management and prognosis. The 2021 revised fifth edition of the WHO classification further integrates molecular alterations for CNS tumor categorization, updating current understanding of the pathophysiology of many of these disease entities. Here, the authors review changes in the new classification for the most common primary adult tumors—gliomas (including astrocytomas, oligodendrogliomas, and ependymomas) and meningiomas—highlighting the key genomic alterations for each group classification to help clinicians interpret them as they consider therapeutic options—including clinical trials and targeted therapies—and discuss the prognosis of these tumors with their patients. The revised, updated 2021 WHO classification also further integrates molecular alterations in the classification of pediatric CNS tumors, but those are not covered in the current review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D. E., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,033
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873
Self-citationEfficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa200 · Cited by 1,789
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., Suvà, M. L., & Bernstein, B. E. (2016) · Nature · doi:10.1038/nature16490 · Cited by 1,288
Pajtler, K. W., Witt, H., Sill, M., Jones, D. T. W., Hovestadt, V., Kratochwil, F., Wani, K., Tatevossian, R., Punchihewa, C., Johann, P., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.002 · Cited by 1,225
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · cited 1×
“2Hydroxyglutarate accumulation has been shown to promote tumorigenesis by competitively inhibiting αketoglutarate– dependent dioxygenases, which include histone lysine demethylases and DNA demethylases.(49,50) This results in histone and DNA hypermethylation with a CpG island methylator phenotype pattern, leading to a…”
BackgroundDecoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq
Venteicher, A. S., Tirosh, I., Hebert, C., Yizhak, K., Neftel, C., Filbin, M. G., Hovestadt, V., Escalante, L. E., Shaw, M. L., Rodman, C., et al. (2017) · Science · doi:10.1126/science.aai8478 · Cited by 1,004
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Sturm, D., Orr, B. A., Toprak, U. H., Hovestadt, V., Jones, D. T. W., Capper, D., Sill, M., Buchhalter, I., Northcott, P. A., Leis, I., et al. (2016) · Cell · doi:10.1016/j.cell.2016.01.015 · Cited by 975
Genomic Analysis of Non- NF2 Meningiomas Reveals Mutations in TRAF7 , KLF4 , AKT1 , and SMO
Clark, V. E., Erson-Omay, E. Z., Serin, A., Yin, J., Cotney, J., Özduman, K., Avşar, T., Li, J., Murray, P. B., Henegariu, O., et al. (2013) · Science · doi:10.1126/science.1233009 · Cited by 912
Brat, D. J., Aldape, K., Colman, H., Holland, E. C., Louis, D. N., Jenkins, R. B., Kleinschmidt-DeMasters, B. K., Perry, A., Reifenberger, G., Stupp, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1913-0 · Cited by 896
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M., Zhelyazkova, B. H., Davidson, C. J., Akhavanfard, S., Cahill, D. P., Aldape, K. D., Betensky, R. A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.005 · Cited by 707
C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma
Parker, M., Mohankumar, K. M., Punchihewa, C., Weinlich, R., Dalton, J. D., Li, Y., Lee, R., Tatevossian, R. G., Phoenix, T. N., Thiruvenkatam, R., et al. (2014) · Nature · doi:10.1038/nature13109 · Cited by 670
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Brastianos, P. K., Horowitz, P. M., Santagata, S., Jones, R. T., McKenna, A., Getz, G., Ligon, K. L., Palescandolo, E., Van Hummelen, P., Ducar, M. D., et al. (2013) · Nature Genetics · doi:10.1038/ng.2526 · Cited by 651
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stütz, A. M., Wang, X., Gallo, M., Garzia, L., Zayne, K., et al. (2014) · Nature · doi:10.1038/nature13108 · Cited by 607
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
Capper, D., Stichel, D., Sahm, F., Jones, D. T. W., Schrimpf, D., Sill, M., Schmid, S., Hovestadt, V., Reuss, D. E., Koelsche, C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1879-y · Cited by 567
The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Bell, R. J. A., Rube, H. T., Kreig, A., Mancini, A., Fouse, S. D., Nagarajan, R. P., Choi, S., Hong, C., He, D., Pekmezci, M., et al. (2015) · Science · doi:10.1126/science.aab0015 · Cited by 566
Emerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma
Witt, H., Mack, S. C., Ryzhova, M., Bender, S., Sill, M., Isserlin, R., Benner, A., Hielscher, T., Milde, T., Remke, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.007 · Cited by 559
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 539
Louis, D. N., Wesseling, P., Aldape, K., Brat, D. J., Capper, D., Cree, I. A., Eberhart, C., Figarella‐Branger, D., Fouladi, M., Fuller, G. N., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12832 · Cited by 525
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Brat, D. J., Aldape, K., Colman, H., Figrarella-Branger, D., Fuller, G. N., Giannini, C., Holland, E. C., Jenkins, R. B., Kleinschmidt-DeMasters, B., Komori, T., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02127-9 · Cited by 520
Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30313-8 · Cited by 495
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas
Shirahata, M., Ono, T., Stichel, D., Schrimpf, D., Reuss, D. E., Sahm, F., Koelsche, C., Wefers, A., Reinhardt, A., Huang, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1849-4 · Cited by 457
Reuss, D. E., Sahm, F., Schrimpf, D., Wiestler, B., Capper, D., Koelsche, C., Schweizer, L., Korshunov, A., Jones, D. T. W., Hovestadt, V., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1370-3 · Cited by 449
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
Self-citationA vaccine targeting mutant IDH1 in newly diagnosed glioma
Platten, M., Bunse, L., Wick, A., Bunse, T., Le Cornet, L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03363-z · Cited by 432
Liu, X.-Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.-A., Fontebasso, A. M., Fleming, A., Hadjadj, D., Schwartzentruber, J., Majewski, J., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1031-3 · Cited by 428
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Sahm, F., Schrimpf, D., Olar, A., Koelsche, C., Reuss, D., Bissel, J., Kratz, A., Capper, D., Schefzyk, S., Hielscher, T., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv377 · Cited by 406
Louis, D. N., Giannini, C., Capper, D., Paulus, W., Figarella-Branger, D., Lopes, M. B., Batchelor, T. T., Cairncross, J. G., van den Bent, M., Wick, W., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1826-y · Cited by 396
Self-citationRecurrent somatic mutations in POLR2A define a distinct subset of meningiomas
Clark, V. E., Harmancı, A. S., Bai, H., Youngblood, M. W., Lee, T. I., Baranoski, J. F., Ercan-Sencicek, A. G., Abraham, B. J., Weintraub, A. S., Hnisz, D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3651 · Cited by 354
van den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clement, P. M., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J. F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00090-5 · Cited by 330
Michaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
The 2016 World Health Organization classification of tumours of the central nervous system
Villa, C., Miquel, C., Mosses, D., Bernier, M., & Di Stefano, A. L. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.04.015 · Cited by 319
Weller, M., Weber, R. G., Willscher, E., Riehmer, V., Hentschel, B., Kreuz, M., Felsberg, J., Beyer, U., Löffler-Wirth, H., Kaulich, K., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1409-0 · Cited by 312
Ellison, D. W., Kocak, M., Figarella-Branger, D., Felice, G., Catherine, G., Pietsch, T., Frappaz, D., Massimino, M., Grill, J., Boyett, J. M., et al. (2011) · Journal of Negative Results in BioMedicine · doi:10.1186/1477-5751-10-7 · Cited by 308
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
Koelsche, C., Sahm, F., Capper, D., Reuss, D., Sturm, D., Jones, D. T. W., Kool, M., Northcott, P. A., Wiestler, B., Böhmer, K., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1195-5 · Cited by 303
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Abedalthagafi, M., Bi, W. L., Aizer, A. A., Merrill, P. H., Brewster, R., Agarwalla, P. K., Listewnik, M. L., Dias-Santagata, D., Thorner, A. R., Van Hummelen, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov316 · Cited by 293
TRK inhibitors in TRK fusion-positive cancers
Drilon, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz282 · Cited by 291
Grassian, A. R., Parker, S. J., Davidson, S. M., Divakaruni, A. S., Green, C. R., Zhang, X., Slocum, K. L., Pu, M., Lin, F., Vickers, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0772-t · Cited by 280
Appay, R., Dehais, C., Maurage, C.-A., Alentorn, A., Carpentier, C., Colin, C., Ducray, F., Escande, F., Idbaih, A., Kamoun, A., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz124 · Cited by 278
cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors
Ellison, D. W., Aldape, K. D., Capper, D., Fouladi, M., Gilbert, M. R., Gilbertson, R. J., Hawkins, C., Merchant, T. E., Pajtler, K., Venneti, S., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12866 · Cited by 278
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
Pajtler, K. W., Wen, J., Sill, M., Lin, T., Orisme, W., Tang, B., Hübner, J.-M., Ramaswamy, V., Jia, S., Dalton, J. D., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1877-0 · Cited by 262
Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas
Smith, M. J., O'Sullivan, J., Bhaskar, S. S., Hadfield, K. D., Poke, G., Caird, J., Sharif, S., Eccles, D., Fitzpatrick, D., Rawluk, D., et al. (2013) · Nature Genetics · doi:10.1038/ng.2552 · Cited by 261
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
Brastianos, P. K., Shankar, G. M., Gill, C. M., Taylor-Weiner, A., Nayyar, N., Panka, D. J., Sullivan, R. J., Frederick, D. T., Abedalthagafi, M., Jones, P. S., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv310 · Cited by 258
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations
Reuss, D. E., Piro, R. M., Jones, D. T. W., Simon, M., Ketter, R., Kool, M., Becker, A., Sahm, F., Pusch, S., Meyer, J., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1093-x · Cited by 256
High Incidence of ActivatingTERTPromoter Mutations in Meningiomas Undergoing Malignant Progression
Goutagny, S., Nault, J. C., Mallet, M., Henin, D., Rossi, J. Z., & Kalamarides, M. (2014) · Brain Pathology · doi:10.1111/bpa.12110 · Cited by 249
Panwalkar, P., Clark, J., Ramaswamy, V., Hawes, D., Yang, F., Dunham, C., Yip, S., Hukin, J., Sun, Y., Schipper, M. J., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1752-4 · Cited by 248
Ellison, D. W., Hawkins, C., Jones, D. T. W., Onar-Thomas, A., Pfister, S. M., Reifenberger, G., & Louis, D. N. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01987-0 · Cited by 247
2-Oxoglutarate-dependent dioxygenases in cancer
Losman, J.-A., Koivunen, P., & Kaelin, W. G. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00303-3 · Cited by 230
cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)
Louis, D. N., Wesseling, P., Paulus, W., Giannini, C., Batchelor, T. T., Cairncross, J. G., Capper, D., Figarella-Branger, D., Lopes, M. B., Wick, W., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1808-0 · Cited by 229
Self-citationWick, W., Roth, P., Hartmann, C., Hau, P., Nakamura, M., Stockhammer, F., Sabel, M. C., Wick, A., Koeppen, S., Ketter, R., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now133 · Cited by 227
Advances in meningioma genetics: novel therapeutic opportunities
Preusser, M., Brastianos, P. K., & Mawrin, C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.168 · Cited by 220
Tesileanu, C. M. S., Dirven, L., Wijnenga, M. M. J., Koekkoek, J. A. F., Vincent, A. J. P. E., Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., van Duinen, S. G., Smits, M., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz200 · Cited by 216
Simon, M., von Deimling, A., Larson, J. M., Wellenreuther, R., Kaskel, P., Waha, A., Warnick, R. E., Tew, J. M., & Menon, A. G. (1995) · PubMed · Cited by 211
Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3052 · Cited by 190
Self-citationMYCN amplification drives an aggressive form of spinal ependymoma
Ghasemi, D. R., Sill, M., Okonechnikov, K., Korshunov, A., Yip, S., Schutz, P. W., Scheie, D., Kruse, A., Harter, P. N., Kastelan, M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02056-2 · Cited by 188
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas
Shankar, G. M., Abedalthagafi, M., Vaubel, R. A., Merrill, P. H., Nayyar, N., Gill, C. M., Brewster, R., Bi, W. L., Agarwalla, P. K., Thorner, A. R., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now235 · Cited by 184
Self-citationMethylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre
Jaunmuktane, Z., Capper, D., Jones, D. T. W., Schrimpf, D., Sill, M., Dutt, M., Suraweera, N., Pfister, S. M., von Deimling, A., & Brandner, S. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0668-8 · Cited by 182
BAP1 mutations in high-grade meningioma: implications for patient care
Shankar, G. M., & Santagata, S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox094 · Cited by 174
Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis
Franz, D. N., Agricola, K., Mays, M., Tudor, C., Care, M. M., Holland‐Bouley, K., Berkowitz, N., Miao, S., Peyrard, S., & Krueger, D. A. (2015) · Annals of Neurology · doi:10.1002/ana.24523 · Cited by 173
Kocakavuk, E., Anderson, K. J., Varn, F. S., Johnson, K. C., Amin, S. B., Sulman, E. P., Lolkema, M. P., Barthel, F. P., & Verhaak, R. G. W. (2021) · Nature Genetics · doi:10.1038/s41588-021-00874-3 · Cited by 166
Leonardi, R., Subramanian, C., Jackowski, S., & Rock, C. O. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.353946 · Cited by 163
A prognostic gene expression signature in infratentorial ependymoma
For the Collaborative Ependymoma Research Network, Wani, K., Armstrong, T. S., Vera-Bolanos, E., Raghunathan, A., Ellison, D., Gilbertson, R., Vaillant, B., Goldman, S., Packer, R. J., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0941-4 · Cited by 162
Andreiuolo, F. D. M., Varlet, P., Tauziède‐Espariat, A., Jünger, S. T., Dörner, E., Dreschmann, V., Kuchelmeister, K., Waha, A., Haberler, C., Slavc, I., et al. (2018) · Brain Pathology · doi:10.1111/bpa.12659 · Cited by 147
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1
Mazor, T., Chesnelong, C., Pankov, A., Jalbert, L. E., Hong, C., Hayes, J. L., Smirnov, I. V., Marshall, R. E., de Souza, C. F., Shen, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708914114 · Cited by 143
Molecular and clinicopathologic features of gliomas harboring NTRK fusions
Torre, M., Vasudevaraja, V., Serrano, J., DeLorenzo, M., Malinowski, S. W., Blandin, A.-F., Pagès, M., Ligon, A. H., Dong, F., Meredith, D. M., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00980-z · Cited by 141
Heterogeneity within the PF-EPN-B ependymoma subgroup
Cavalli, F. M. G., Hübner, J.-M., Sharma, T. S., Luu, B., Sill, M., Zápotocký, M., Mack, S. C., Witt, H., Lin, T., Shih, D. J. H., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1888-x · Cited by 135
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
Aylwin, S. J. B., Bódi, I., & Beaney, R. P. (2015) · Pituitary · doi:10.1007/s11102-015-0663-4 · Cited by 132
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients
Vera‐Bolanos, E., Aldape, K., Yuan, Y., Wu, J., Wani, K., Necesito-Reyes, M. J., Colman, H., Dhall, G., Lieberman, F. S., Métellus, P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou162 · Cited by 132
Wahl, M. T., Phillips, J. J., Molinaro, A. M., Lin, Y., Perry, A., Haas-Kogan, D. A., Costello, J., Dayal, M., Butowski, N. A., Clarke, J. L., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now176 · Cited by 131
Goutagny, S., Yang, H. W., Zucman‐Rossi, J., Chan, J. A.-W., Dreyfuss, J. M., Park, P. J., Black, P. M., Giovannini, M., Carroll, R. S., & Kalamarides, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0891 · Cited by 126
Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas
Juratli, T. A., Thiede, C., Koerner, M. V. A., Tummala, S. S., Daubner, D., Shankar, G. M., Williams, E. A., Martinez‐Lage, M., Soucek, S., Robel, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22650 · Cited by 125
Classification of meningiomas—advances and controversies
Harter, P. N., Braun, Y., & Plate, K. H. (2017) · Chinese Clinical Oncology · doi:10.21037/cco.2017.05.02 · Cited by 122
The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
Klesse, L. J., Jordan, J. T., Radtke, H. B., Rosser, T. L., Schorry, E. K., Ullrich, N. J., Viskochil, D. H., Knight, P. B., Plotkin, S. R., & Yohay, K. H. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0069 · Cited by 120
Abedalthagafi, M., Phillips, J. J., Kim, G., Mueller, S., Haas-Kogen, D. A., Marshall, R. E., Croul, S. E., Santi, M., Cheng, J. Q., Zhou, S., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.90 · Cited by 119
Finn, R. S., Martín, M., Rugo, H. S., Jones, S. E., Im, S., Gelmon, K. A., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.507 · Cited by 109
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations
Juratli, T. A., Jones, P. S., Wang, N., Subramanian, M. P., Aylwin, S. J. B., Odia, Y., Rostami, E., Gudjonsson, O., Shaw, B. L., Cahill, D. P., et al. (2019) · Cancer · doi:10.1002/cncr.32197 · Cited by 103
Sahm, F., Bissel, J., Koelsche, C., Schweizer, L., Capper, D., Reuß, D., Böhmer, K., Laß, U., Göck, T., Kalis, K., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1187-5 · Cited by 101
Reitman, Z. J., Duncan, C. G., Poteet, E. C., Winters, A., Yan, L., Gooden, D. M., Spasojević, I., Boros, L. G., Yang, S.-H., & Yan, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.575183 · Cited by 97
Integrated molecular characterization of IDH ‐mutant glioblastomas
Korshunov, A., Casalini, B., Chávez, L., Hielscher, T., Sill, M., Ryzhova, M. V., Sharma, T. S., Schrimpf, D., Stichel, D., Capper, D., et al. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12523 · Cited by 93
The cIMPACT-NOW updates and their significance to current neuro-oncology practice
Castro, L. N. G., & Wesseling, P. (2020) · Neuro-Oncology Practice · doi:10.1093/nop/npaa055 · Cited by 78
Wick, A., Bähr, O., Schüler, M., Rohrberg, K. S., Chawla, S. P., Jankú, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4256 · Cited by 75
Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions
Jurić, V., & Murphy, B. M. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.105 · Cited by 56
P‑glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability
Martínez-Chávez, A., van Hoppe, S., Rosing, H., Lebre, M. C., Tibben, M. M., Beijnen, J. H., & Schinkel, A. H. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00475 · Cited by 50
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas
Han, C. H., & Batchelor, T. T. (2017) · Chinese Clinical Oncology · doi:10.21037/cco.2017.06.11 · Cited by 44
Self-citationDas, A., Alshareef, M., Santos, J. L. M., Porto, G. B. F., McDonald, D. G., Infinger, L. K., Vandergrift, W. A., Lindhorst, S., Varma, A. K., Patel, S. J., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02341-7 · Cited by 22
Cited by
Torp, S. H., Solheim, O., & Skjulsvik, A. J. (2022) · Acta Neurochirurgica · doi:10.1007/s00701-022-05301-y · Cited by 303
Metadata
- Authors
- Gritsch, S., Batchelor, T. T., & Gonzalez Castro, L. N.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2021-10-11
- Volume
- 128
- Issue
- 1
- Pages
- 47-58
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W3206733738
- Cited by
- 372
- References
- 107
- FWCI
- 27.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.